Lonza Group AG

You've been on both sides of this.

So with Lonza as the CDMO now at J&J as the sponsor organization, how real and justified is the concern that smaller biotech clients may be bro-- be, may be deprioritized by CDMOs, uh, because of larger clients that they have in their slots?

Yeah.

So this is actually a good point, I would say, especially when I've been in the other side of the table.

So in some respects, it was lucky for us to be there at the right time and lucky that we were big enough that Amgen could take us on board, not take too much of a risk and grow with us.

And so understanding that shift between these two companies and the reasons why they made their decisions went, okay, well, you know, Lonza is in the camp of Genentech.

They really didn't need to do that at the time, although they have.

But many other companies like Sanofi and others, they had their own reasons.

Philippe has a really amazing CV.

He spent around three decades in global roles across Novartis, Lonza and Saiba before turning his attention full-time to the future of health, which I think is an amazing decision.

He's an international keynote speaker, an innovation advisor and board member to companies across Europe, Middle East and Asia.

and a passionate advocate for what he calls digitalization humanism.

Her company engineers reproducible, animal-free protein matrices, so-called bio-inks that let researchers tune mechanics and biology independently, batch after batch.

Sandra brings 15 years of drug substance and drug product experience from Lonza, Medinova, Baxalta and Biogen to this challenge.

Let's get into it.

Are you juggling the complexities of CMC development while trying to enjoy the beauty of biotech? Have you ever wondered if there's a way to simplify bioprocessing? Welcome to the Smart Biotech Scientist podcast where we're diving headfirst into the very challenges you face.

Along the way, he's experienced every side of the industry from innovator, CDMO, public company, private equity and everything in between.

His career has been shaped by change, complexity, and reinvention, leading global manufacturing networks at Baxter, Lonza, Center of Breakthrough Medicines, and now is the CEO of SK Pharmateco.

This episode is about why adversity builds resilience, why CDMOs expose the true quality of leadership, and what it really takes to lead organizations through complexity, scarcity, and change.

You're welcome to Active Ingredients.

You know, parents don't become younger again.

And we got the offer.

I got the offer to move to Lonza, head of operations.

My first reaction was I would never work for a CDMO.

And the second speaker, eh, is John Boyd.

And John is the director of tissue acquisi- eh, acquisition at Lonza, leading a multidisciplinary team that supports clinical and research initiative relying on donated organs and tissues and cells.

And additional, Jonathan is the founder and CEO of AlloEd, which provide technical training and education to current and future donation and transplant professionals worldwide.

And John, you will share your, the perspective international education initiatives and approaches that support the capacity building and professional development for Allied Health professionals working in organ donation and transplantation system.